MEK-ing the Most of It: Strategies to Co-target Gαq and MAPK in Uveal Melanoma

Abstract Most uveal melanomas harbor mutations in Gαq and show constitutive MAPK activation. Although MEK inhibition has some efficacy against uveal melanoma, clinical responses are typically poor. The Gαq inhibitor-MEK inhibitor combination showed prolonged suppression of MAPK signaling in preclinical uveal melanoma models and led to improved therapeutic responses. See related article by Hitchman et al., p. 1476